Introgen’s INGN 225 Molecular Cancer Vaccine Demonstrates Promising Results in Phase 2 Trial
Approximately half of patients with advanced small cell lung cancer responded to Introgen Therapeutics, Inc.’s INGN 225 molecular cancer vaccine in combination with subsequent chemotherapy.
This entry was posted on Monday, January 29th, 2007 at 9:38 am and is filed under Research, Small-Cell. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.